Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Cell Death Differ. 2022 Jan;29(1):54-64. doi: 10.1038/s41418-021-00836-6. Epub 2021 Jul 22.
Breast cancer heterogeneity has made it challenging to identify mechanisms critical to the initial stages of their genesis in vivo. Here, we sought to interrogate the role of YB-1 in newly arising human breast cancers as well as in established cell lines. In a first series of experiments, we found that short-hairpin RNA-mediated knockdown of YB-1 in MDA-MB-231 cells blocked both their local tumour-forming and lung-colonising activity in immunodeficient mice. Conversely, upregulated expression of YB-1 enhanced the poor in vivo tumorigenicity of T47D cells. We then found that YB-1 knockdown also inhibits the initial generation in mice of invasive ductal carcinomas and ductal carcinomas in situ from freshly isolated human mammary cells transduced, respectively, with KRAS or myristoylated-AKT1. Interestingly, increased expression of HIF1α and G3BP1, two YB-1 translational targets and elements of a stress-adaptive programme, mirrored the levels of YB-1 in both transformed primary and established MDA-MB-231 breast cancer cells.
乳腺癌异质性使得确定其体内发生初始阶段关键机制的难度加大。在这里,我们试图探究 YB-1 在新出现的人类乳腺癌以及已建立的细胞系中的作用。在一系列初步实验中,我们发现短发夹 RNA 介导的 MDA-MB-231 细胞中 YB-1 的敲低阻止了其在免疫缺陷小鼠中的局部肿瘤形成和肺定植活性。相反,YB-1 的上调表达增强了 T47D 细胞在体内的不良致瘤性。然后我们发现,YB-1 的敲低也抑制了从分别用 KRAS 或 myristoylated-AKT1 转导的新鲜分离的人乳腺细胞在小鼠中初始生成侵袭性导管癌和原位导管癌。有趣的是,两种 YB-1 翻译靶标 HIF1α 和 G3BP1 的表达增加,以及应激适应程序的元素,反映了转化的原发性和已建立的 MDA-MB-231 乳腺癌细胞中 YB-1 的水平。